Medscape Top 10 for Critical Care in 2010

Highlights from the Medscape Top 10 for Critical Care in 2010:
確かに今年話題になった issuesですね。

  1. New Brain Death Guidelines Issued

    Updated for the first time in 15 years, new American Academy of Neurology guidelines provide step-by-step instructions for determining brain death in adults.

  2. Dopamine or Norepinephrine for Shock?

    The age-old question of which drug is better for shock continues to stimulate study and debate.

  3. Controversies in the Treatment of Sepsis

    This article discusses the controversial roles of intensive insulin therapy, corticosteroids, and activated protein C in the treatment of sepsis.

  4. Tigecycline Linked to Increased Mortality Risk

    The increased mortality risk is most evident in patients treated for hospital-acquired pneumonia and particularly ventilator-associated pneumonia, which is an unapproved indication.

  5. FDA Again Warns Against IV Administration of Nimodipine

    The FDA again reminded clinicians that nimodipine should be given only by mouth or through a feeding tube and never by IV administration, a method that could be fatal.

  6. High vs Low Positive End-Expiratory Pressure in Ventilatory Management of Adults

    A meta-analysis of existing research reveals which patients might benefit from lower positive end-expiratory pressure levels.

  7. Management of Bleeding Following Major Trauma: an Updated European Guideline

    This evidence-based approach for managing bleeding in trauma patients makes the GRADE.

  8. Procalcitonin-Guided Antibiotic Therapy

    Is procalcitonin-guided antibiotic therapy ready for prime time?

  9. A Cost-Minimization Analysis of Dexmedetomidine Compared With Midazolam For Long-Term Sedation In The Intensive Care Unit

    In this study, the use of dexmedetomidine for long-term sedation saved $9679 per ICU patient compared to midazolam.

  10. Healthcare Reform Resource Center
    The evolving debate was chronicled by Medscape throughout 2010. Bookmark this page so that you’ll have access to the latest information as it becomes available.


    About this entry